Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.48 |
| ▸ | BTK | Q06187 | 12/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL673183 | 0.81 | JAK3 (0.47) | JAK3FLT4 | |
| SCHEMBL1663059 | 0.76 | JAK3 (0.49) | JAK3BTKPTK2FLT4 | |
| SCHEMBL672922 | 0.75 | JAK1 (0.52) | JAK3BTK | |
| SCHEMBL12801969 | 0.74 | LRRK2 (0.39) | MAP3K14 | |
| SCHEMBL1663056 | 0.74 | JAK3 (0.49) | JAK3PTK2FLT4 | |
| SCHEMBL12796498 | 0.72 | JAK3 (0.45) | JAK3FLT4 | |
| SCHEMBL16812379 | 0.71 | JAK3 (0.61) | JAK3 | |
| SCHEMBL12797172 | 0.70 | JAK3 (0.44) | JAK3PTK2FLT4 | |
| SCHEMBL12796456 | 0.70 | JAK3 (0.52) | JAK3PTK2FLT4 | |
| SCHEMBL12795242 | 0.69 | FLT4 (0.46) | JAK3PTK2FLT4MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| EP-2566867-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011134831-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK3 2/4885BTK 42/4885PTK2 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.